Ulonivirine not checked

Merck & Co. · MK-8507

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
3 active
10 in total · 2 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“ISL/ULO fixed-dose combination 2 mg/200 mg oral tablet administered qw for 96 weeks”In the company’s words, NCT07266831 on ClinicalTrials.gov
Tested for
Human Immunodeficiency Virus Type 1 (HIV-1) Infection (2 trials), Hepatic Insufficiency
Main trialPhase 2/3
“Researchers are looking for new ways to treat HIV-1 (Human Immunodeficiency Virus Type 1). The usual (standard) treatment for HIV-1 is antiretroviral therapy (ART), which includes taking medicines to lower the amount of HIV-1 in the body. Standard ART helps people live longer, but people must take up to 3 medicines up to twice a day. Standard ART may also cause other health problems. Researchers want to know if a study ART works as well as a standard ART to treat HIV-1. The study ART combines 2 medicines, islatravir and ulonivirine, and is taken once a week. The goals of this study are to…”In the company’s words, NCT07266831 on ClinicalTrials.gov
Other names
MK-8507 · ULO

Other drugs for Human Immunodeficiency Virus Type 1 (HIV-1) Infection

All 24 drugs for Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Coming up3

Changes2

Last 90 days

Trials10

TrialPhaseCompletesWhat it tests
Phase 2/3Recruiting 1 Feb 2029 A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)
Phase 2Active, not recruiting 10 Aug 2027 A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)
Phase 1Not yet recruiting 29 Jun 2027 Ulonivirine (MK-8507) in Participants With Mild or Moderate Hepatic Impairment (MK-8507-014)
Phase 2Completed 30 Jan 2025 Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]
Phase 1Completed 16 Jul 2015 Evaluation of Safety, Tolerability, Pharmacokinetics, and Antiretroviral Activity of Ulonivirine (MK-8507) in Human Immunodeficiency Virus (HIV-1)-Infected Participants (MK-8507-003)
Phase 1Completed 23 Jun 2024 A Study of MK-8507 and Islatravir (MK-8591) in Healthy Adult Participants (MK-8507-016)
Phase 1Completed 11 Nov 2025 A Study of [14C]Ulonivirine ([14C]MK-8507) in Healthy Adults (MK-8507-006)
Phase 1Completed 9 Apr 2026 A Clinical Trial to Evaluate the Effect of Ulonivirine (MK-8507) on Heart Rhythm in Healthy Adults (MK-8507-012)
Phase 1Completed 23 May 2026 A Clinical Study of Ulonivirine (MK-8507) With Atorvastatin and Metformin in Healthy Adults (MK-8507-018)
Phase 1Completed 29 Sep 2026 A Study of Ulonivirine (MK-8507) and Methadone in Healthy Volunteers (MK-8507-019)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Ulonivirine

Following is part of Solo: you see every change to Ulonivirine the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in